Regencell Bioscience Holdings annual free cash flow
2020
2022
2023
2024
2025
Regencell Bioscience Holdings Free Cash Flow (FCF) History (RGC)
Regencell Bioscience Holdings reported −$3.3M in free cash flow for fiscal 2025, an increase of $740,798 from the previous fiscal year.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-06-30 | −$3.3M | $740,798 | — | — |
| 2024 | 2024-06-30 | −$4.0M | $983,278 | — | — |
| 2023 | 2023-06-30 | −$5.0M | $1.1M | — | — |
| 2022 | 2022-06-30 | −$6.0M | — | — | — |
| 2020 | 2020-06-30 | −$844,410 | — | — | — |
Regencell Bioscience Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$844,410 to −$3.3M, a net decrease of $2.4M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Regencell Bioscience Holdings source filings ↗